The proposed Critical Medicines Act (CMA) offers a pivotal opportunity to strengthen the EU’s pharmaceutical resilience. By embracing global supply chain diversification, open trade and strategic international cooperation, the EU can reinforce access to essential medicines while preserving its competitiveness. However, to succeed, the CMA must steer clear of protectionist approaches that risk undermining the internal market and disrupting supply. Instead, it should promote pragmatic, market-driven solutions with strong industry involvement. Read our full position to explore how the EU can foster a stable, secure and innovation-friendly environment for medicines.